Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

NCT02178241 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

NIH

Sponsor class

Conditions

Metastatic Ureter Carcinoma
Metastatic Urethral Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Stage III Ureter Cancer AJCC v7
Stage III Urethral Cancer AJCC v7
Stage IV Bladder Urothelial Carcinoma AJCC v7
Stage IV Ureter Cancer AJCC v7
Stage IV Urethral Cancer AJCC v7
Ureter Urothelial Carcinoma
Urethral Urothelial Carcinoma

Interventions

DRUG: Eribulin Mesylate
DRUG: Gemcitabine Hydrochloride

Sponsor

National Cancer Institute (NCI)